Press Releases

Nymox Files For Marketing Approval For Fexapotide Triflutate in Europe

May 3, 2017:

May 3, 2017: Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce today that the Company has filed to seek approval for marketing authorization for Fexapotide Triflutate in five European countries, comprising the Netherlands, the UK, Germany, France and Spain.


Nymox Provides Update on Fexapotide Development

March 29, 2017:

Nymox Pharmaceutical Corporation provided an update today on the Companys development activities for Fexapotide Triflutate, its new drug for prostate enlargement.


Nymox Reports Additional Positive Results From Completed Fexapotide BPH Phase 3 Studies Showing Significant Early Response and First-Line Efficacy

November 29, 2016:

Nymox Pharmaceutical Corporation is pleased to announce that new Phase 3 prospective randomized clinical trial results have confirmed that patients who received fexapotide as their initial treatment for BPH (prostate enlargement) had superior efficacy results as early as 10 days compared to control patients who received placebo or who had prior history of other BPH medical treatments.


Nymox Reports Successful New Phase 3 Long-Term Fexapotide Repeat Injection BPH Trial Results: Lasting Symptomatic Improvement Up To 6 Years After Single Repeated Treatment

October 11, 2016:

Nymox Pharmaceutical Corporation is pleased to announce successful new study results from the long-term repeated injection group from the U.S. Phase 3 trials for fexapotide, the Companys lead compound in late stage development for enlarged prostate (BPH) and for localized prostate cancer.


Nymox’s New Phase 3 Long-Term U.S. Results For Prostate Enlargement Drug Fexapotide Show

August 29, 2016:

Nymox Pharmaceutical Corporation lead drug fexapotide which has been in development for over a decade and which has been tested by expert clinical trial investigative teams in over 70 distinguished clinical trial centers…


Nymox Reports Successful New Long-Term Fexapotide Placebo Crossover Study Results: Major Reduction in Incidence of Surgery

August 24, 2016:

Nymox Pharmaceutical Corporation is pleased to announce successful new study results from the long-term blinded placebo crossover group from the U.S. Phase 3 trials for fexapotide, the Companys lead compound in late stage development for enlarged prostate (BPH) and for localized prostate cancer.


Nymox Announces Private Placements of $2.24 Million

August 17, 2016:

Nymox Pharmaceutical Corporation is pleased to announce that it has recently closed private placements and other investments in the Company for a total of $2.24 million.


Nymox Announces Prostate Drug Progress

August 11, 2016:

Nymox Pharmaceutical Corporation is pleased to announce major progress in the evidence for the safety and efficacy of fexapotide, the Companys Phase 3 drug in the final stages of development for prostate enlargement (BPH) and for low grade prostate cancer.


Nymox Reports Long-Term Prostate Cancer Results in 7 Year Prospective Study of 995 U.S. Middle-Aged and Elderly Men Without Cancer

June 22, 2016:

Nymox Pharmaceutical Corporation announced today results from the Companys 7 year prospective placebo controlled double blind studies of treatment of 995 U.S. men with the Companys lead drug fexapotide.


Nymox Announces Prostate Cancer Clinical Trial Results From Completed 18 Month Endpoint Study

February 9, 2016:

Nymox Pharmaceutical Corporation today announced results from the completion of the Companys U.S. 40 month (18 month outcomes) localized prostate cancer Phase 2 NX03-0040 clinical trial of fexapotide triflutate (NX-1207).